Home / Peptide legality / Pennsylvania
Are peptides legal in Pennsylvania?
Pennsylvania has no peptide-specific ban, so peptide legality tracks the federal floor: a peptide is lawful in Pennsylvania only when it is an FDA-approved product prescribed by a licensed clinician or is compounded from a permitted substance by a properly licensed pharmacy, which places most research peptides in a gray zone.
Legal status overview
Pennsylvania sits in a gray zone because the state has not enacted rules above the federal floor, so what may lawfully be dispensed or compounded is set chiefly by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and by FDA policy. FDA-approved peptide medicines, such as Wegovy® (semaglutide) and approved somatropin products, are legal when prescribed by a Pennsylvania-licensed provider for an appropriate use. Compounded peptides are a different matter: they are not FDA-approved, not a generic, and not evaluated by the FDA, and they are lawful only when made from an eligible substance for a documented patient-specific need by a pharmacy the Pennsylvania State Board of Pharmacy licenses. Many popular research peptides, including BPC-157 and TB-500, are not on FDA's permitted bulk substances list, so they cannot be lawfully compounded today regardless of state silence.
Key points
- Pennsylvania has not published a peptide-specific rule, so eligibility is governed by the federal 503A and 503B framework and by the licensing standards of the Pennsylvania State Board of Pharmacy. [5]
- FDA-approved peptide drugs, including Wegovy® (semaglutide) and approved somatropin products, are legal in Pennsylvania when a licensed clinician prescribes them for an appropriate indication. [1]
- Compounded peptides are not FDA-approved, not a generic, and not evaluated by the FDA; in Pennsylvania they are lawful only through a licensed 503A pharmacy or 503B outsourcing facility for a documented patient-specific reason. [2]
- The FDA determined the semaglutide and tirzepatide shortages resolved in early 2025 and wound down large-scale compounding discretion, so routine compounding of these GLP-1 medicines is no longer permitted in Pennsylvania. [7]
- BPC-157 was removed from FDA's Category 2 do-not-compound list in April 2026, but removal from that list did not add it to the permitted list, so it still cannot be lawfully compounded under Section 503A. [3]
- An FDA advisory committee voted in July 2026 to recommend BPC-157 for the permitted Category 1 list tied to a specific proposed indication, but the FDA has not finalized that action, so the substance remains in regulatory limbo. [4]
- Human growth hormone (somatropin) carries an extra federal restriction: distributing it for any use not authorized by the FDA is a federal crime under 21 U.S.C. 333(e), and this applies in Pennsylvania. [6]
- Pennsylvania recognizes telehealth prescribing, but a valid provider-patient relationship and documented clinical justification are still required before any peptide prescription. (no source found)
Compound-by-compound status
| BPC-157 Gray area | Not on FDA's permitted 503A bulk substances list; removed from the Category 2 do-not-compound list in April 2026 but not yet permitted, so not lawfully compoundable in Pennsylvania today. |
|---|---|
| GLP-1 class (semaglutide, tirzepatide) Restricted | Brand products such as Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound® (tirzepatide) are legal by prescription; compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA, and are limited to documented patient-specific need now that the shortages are resolved. |
| TB-500 (thymosin beta-4) Restricted | No FDA-approved human product and not a permitted compounding substance, so it cannot be lawfully compounded or marketed for human use in Pennsylvania. |
| Growth hormone / somatropin Restricted | FDA-approved somatropin is legal by prescription for approved indications only; distribution for non-approved uses is prohibited under federal law 21 U.S.C. 333(e). |
Frequently asked questions
Is BPC-157 legal in Pennsylvania?
There is no Pennsylvania law that names BPC-157, so its status follows the federal framework. It is not on FDA's permitted list of substances for compounding, so a pharmacy cannot lawfully compound it today, even though it was taken off the Category 2 do-not-compound list in April 2026. This is information, not medical or legal advice.
Can I get compounded semaglutide in Pennsylvania?
Only in limited circumstances. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA. Because the shortage was declared resolved in 2025, a licensed provider must document a patient-specific clinical reason, and the prescription must run through a licensed compounding pharmacy.
Does Pennsylvania have its own peptide ban?
No published peptide-specific ban was found. Pennsylvania defers to the federal 503A and 503B eligibility rules and to the Pennsylvania State Board of Pharmacy's licensing and compounding standards.
Are FDA-approved peptide medications legal here?
Yes. Approved products such as Wegovy® (semaglutide) and approved somatropin medicines are legal in Pennsylvania when prescribed by a licensed clinician for an appropriate use.
Can I buy research-grade peptides for personal use?
Products labeled research-grade or for research use only are not approved for human use and are not lawful to prescribe, dispense, or administer to patients. This is general information, not advice.
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (retrieved 2026-09-21)
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (retrieved 2026-09-21)
- BPC-157 in 2026: Why Regulatory Limbo Is Not the Same as a Green Light (Holt Law) (retrieved 2026-09-21)
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (FDA) (retrieved 2026-09-21)
- Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides (Sheppard Mullin) (retrieved 2026-09-21)
- 21 U.S. Code § 333 - Penalties (Legal Information Institute) (retrieved 2026-09-21)
- FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide (NCPA) (retrieved 2026-09-21)
Last researched: 2026-09-21.